A Phase 3 interventional study of paliperidone palmitate injection and oral antipsychotics in Schizophrenia, sponsored by Janssen-Cilag International NV. Completed at 99 sites in 25 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-02-18.
Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 7th largest by enrollment, is one of 8 that started in 2010, is one of 41 in phase 3, and was the 55th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 8 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 769 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag International NV, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag International NV is the lead sponsor of 67 studies on the registry; none are open to participants now.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 9th largest by enrollment of the 176 interventional ones that give a count, is one of 13 that started in 2010, is one of 74 in phase 3, and was the 133rd registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy (how well the drug works; primarily through the time to relapse) of long-acting injectable paliperidone palmitate compared to treatment as usual with orally administered antipsychotics in monotherapy over 24 months in the treatment of recently diagnosed (1-5 years since diagnosis) schizophrenia.
This is a randomized (study drug assigned by chance), open-label (both physician and patient know the name of the assigned drug), rater-blinded (the person who assesses the condition of the patient does not know the name of the assigned drug), active-controlled, parallel-group, multicenter, prospective international study of paliperidone palmitate versus treatment as usual with oral antipsychotic agents in monotherapy in the prevention of relapse (return of symptoms). Patients who have been recently diagnosed with schizophrenia (within 5 years) and are suffering from a schizophrenic relapse (return of symptoms of schizophrenia) will be enrolled. This study consists of a 2-week initial acute oral treatment phase, followed by a treatment phase (core phase) until relapse or up to maximally 24 months, whichever comes first. Prior to a 2-week oral treatment phase, patients will be randomly (by chance) assigned in a 1:1 ratio to receive treatment with paliperidone palmitate injection (once-monthly) or oral antipsychotic medication (daily). Patients randomized to paliperidone palmitate will first receive oral paliperidone ER once daily for 2 weeks followed by paliperidone palmitate injections at a dose of 150 mg eq. on Day 1, 100 mg eq. on Day 8 both in the deltoid muscle and 75 mg eq. on Day 38 and doses in a dose range of 25 to 150 mg eq. in either the deltoid or the gluteal muscle thereafter. Patients randomized to oral comparator arm will receive oral antipsychotics (haloperidol, paliperidone ER, risperidone, olanzapine, quetiapine or aripiprazole) as per investigator discretion and prescribed according to the label. Total treatment duration is maximally 24 months. During the 24 month treatment phase, investigators will be allowed to flexibly decrease or increase the dose of paliperidone palmitate with one dose level in the range of 25 to 150 mg eq. or the oral antipsychotic in the respective locally approved dose range, all according to the patient's clinical needs. The primary endpoint of the 24-month treatment phase will be the time to relapse. Safety will be monitored by evaluating Adverse Events (AEs), rating of extrapyramidal symptoms (symptoms like abnormal muscle movements, abnormal movements of the tongue or jaw, slow or sustained muscle contractions, muscle spasms, shaking, abnormal movements of the eyes, involuntary muscle contractions, slow movements, or restlessness), vital signs measurements (including heart rate and blood pressure), body weight and physical examination findings. A urine pregnancy test will be performed in females of childbearing potential. Adverse events (unintended, but not necessarily unexpected, results of therapy that can be unpleasant or dangerous), associated concomitant medications, and symptoms of relapse will be recorded as needed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
paliperidone palmitate injection with 150 mg equivalent on Day 1 100 mg equivalent on Day 8 75 mg equivalent on Day 38 and flexible dosing with 25 50 75 100 or 150 mg equivalent once monthly thereafter
Drug: paliperidone palmitate injection
oral antipsychotics daily treatment according to local label for maximally 24 months
Drug: oral antipsychotics
injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter
daily treatment according to local label for maximally 24 months
Time to First Relapse Event
Number of days from baseline (day 1 of core phase) to relapse as evaluated according the Csernansky criteria. A patient was considered to have relapsed if they met one or more of the following criteria: (1) psychiatric hospitalization; (2) an increase in the level of psychiatric care and an increase of 25 percent (%) from baseline in the Positive And Negative Syndrome Score (PANSS) total score (or an increase of 10 points if the baseline score was 40 or less); (3) deliberate self-injury; (4) suicidal or homicidal ideation that was clinically significant in the investigator's judgment; (5) violent behavior resulting in clinically significant injury to another person or property damage; (6) substantial clinical deterioration, defined as a change score of 6 ("much worse") or 7 ("very much worse") on the Clinical Global Impressions Scale (CGI-C); and/or (7) the required dose of the antipsychotic exceeds the maximum approved dose.
Time frame: from baseline (Day 1 of core phase) up to maximally 24 months.
Number of Participants With a Relapse Event
Number of participants with a relapse event with relapses evaluated according the Csernansky criteria. A patient was considered to have relapsed if they met one or more of the following criteria: (1) psychiatric hospitalization; (2) an increase in the level of psychiatric care and an increase of 25% from baseline in the PANSS total score (or an increase of 10 points if the baseline score was 40 or less); (3) deliberate self-injury; (4) suicidal or homicidal ideation that was clinically significant in the investigator's judgment; (5) violent behavior resulting in clinically significant injury to another person or property damage; (6) substantial clinical deterioration, defined as a change score of 6 ("much worse") or 7 ("very much worse") on the Clinical Global Impressions Scale (CGI-C); and/or (7) the required dose of the antipsychotic exceeds the maximum approved dose.
Time frame: from baseline (Day 1 of core phase) up to maximally 24 months
Percentage of Treatment Responders
The proportion of patients achieving a treatment response, defined as a ≥30% decrease (i.e., improvement) in Positive and Negative Syndrome Scale (PANSS) total score from baseline to endpoint. The PANSS is a 30-item scale (Range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate increased severity of schizophrenia symptoms.
Time frame: from baseline (day 1 of core phase) up to maximally 24 months
Change From Baseline in PANSS Total Score
Change from baseline in the PANSS: The PANSS is a 30-item scale (Range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.
Time frame: Baseline, day 8, month 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, 24
Change From Baseline in PANSS Subscale Score
Change from baseline in positive symptom, negative symptom and general psychopathology subscales of the PANSS scale. The PANSS scale is designed to assess symptoms of schizophrenia by means of the 30-items. The PANSS scale provides subscores for 3 subscales, that is, the positive symptoms subscale (7 items, range 7-49), the negative symptoms subscale (7 items, range 7-49), and the general psychopathology subscale (16 items, range 16-112). Each item of the scale is to be scored on a scale of 1 (absent) to 7 (extreme). Higher scores indicate higher severity of schizophrenia symptoms.
Time frame: Baseline (day 1 of core phase), day 8, month 12, 24
Change From Baseline in PANSS Marder Factor Scores
Change from baseline in schizophrenia symptoms were assessed through the following PANSS factor scores as described by Marder: (1) positive symptoms (range 8-56): sum of delusions, hallucinatory behavior, grandiosity, suspiciousness, stereotyped thinking, somatic concern, unusual thought content, lack of judgment and insight; (2) negative symptoms (range 7-49): sum of blunted affect, emotional withdrawal, poor rapport, passive social withdrawal, lack of spontaneity, motor retardation, and active social avoidance; (3) disorganized thoughts (range 7-49): sum of conceptual disorganization, difficulty in abstract thinking, mannerisms and posturing, disorientation, poor attention, disturbance of volition, and preoccupation; (4) uncontrolled hostility/excitement (range 4-28): sum of excitement, hostility, uncooperativeness and poor impulse control; (5) anxiety/depression (range 4-28): sum of anxiety, guilt feelings, tension, and depression. Higher scores indicate higher severity of symptoms
Time frame: Baseline (day 1 of core phase), day 8, month 12 and 24
Change From Baseline in Clinical Global Impression Severity (CGI-S) Score
The Clinical Global Impression Severity (CGI-S) rating scale is a 7 point global clinical assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate higher impression of illness severity.
Time frame: Baseline (day 1 of core phase), day 8, month 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, 24
Clinical Global Impression-Change (CGI-C)
The Clinical Global Impression-Change (CGI-C) rating scale is used to rate the change in severity of the patient's illness compared to baseline (day 1 of core phase) on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: Month 24 and endpoint
Changes From Baseline in Personal and Social Performance (PSP) Total Score
The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100, divided into 10 equal intervals to rate degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on 4 domains there will be 1 total score. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.
Time frame: baseline (day 1 of core phase), month 1, 3, 6, 9, 12, 15, 18, 21 and 24
Change From Baseline in Short Form-36 Health Survey (SF-36)
The Short Form-36 Health Survey (SF-36) is a measure of Participant-reported health status. It is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Two summary scale scores are computed based on weighted combinations of the 8 subscale scores: the Physical Component Summary and the Mental Component Summary. Each summary scale score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status.
Time frame: baseline (day 1 of core phase), month 6, 12 and 24
Change From Baseline in EuroQol 5-Dimensional Questionnaire (EQ-5D) VAS Score
The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analog scale, with 0 representing the worst imaginable health state and 100 representing the best imaginable health state. The EQ VAS is used as a quantitative measure of health outcome as judged by the individual respondent.
Time frame: baseline (day 1 of core phase), month 6, 12 and 24
Change From Baseline in EuroQol 5-Dimensional Questionnaire (EQ-5D) Index Score
The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "full health" and 0 representing dead. A higher score indicates an improvement in health in the Health Status Index.
Time frame: baseline (day 1 of core phase), month 6, 12 and 24
Change From Baseline in Subjective Well-Being Under Neuroleptics-Short Form (SWN-S) Total Score
The SWN-S is a patient self-rated scale developed to measure the subjective well-being for the previous 7 days of a patient under neuroleptic treatment. The SWN-S consists of 20 items (each item is rated from 1=not at all to 6=very much). The total score ranges from 20 to 120 with higher score indicating greater subjective well-being.
Time frame: baseline (day 1 of core phase), month 6, 12 and 24
Change From Baseline in Patient's Treatment Satisfaction
Patient's satisfaction with medication was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM is divided into 4 subscales (effectiveness, side effects, convenience, and global satisfaction), with the value of each subscale ranging from 0 to 100. Higher scores indicate greater treatment satisfaction.
Time frame: baseline (day 1 of core phase), month 12 and 24
Change From Baseline in Physician's Treatment Satisfaction
Physician's treatment satisfaction was assessed using the physician's treatment satisfaction scale which is designed to rate 4 aspects of treatment (efficacy, safety, mode of administration, and overall satisfaction), each on a scale ranging from 1 (extremely satisfied) to 7 (extremely dissatisfied).
Time frame: baseline (day 1 of core phase), month 12 and 24
| Milestone | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Started | 376 | 388 |
| Completed | 352 | 363 |
| Not completed | 24 | 25 |
| Withdrew: Missing responder assessment | 10 | 12 |
| Withdrew: Stopped; non-responder after 2 weeks | 6 | 6 |
| Withdrew: Deviation; non-responder after 2 weeks | 6 | 7 |
| Withdrew: Responder after 2 weeks, but stopped | 2 | 0 |
| Milestone | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Started | 352 | 363 |
| Completed | 272 | 266 |
| Not completed | 80 | 97 |
| Withdrew: Adverse event | 14 | 11 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Lack of efficacy | 2 | 6 |
| Withdrew: Lost to follow-up | 4 | 5 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Withdrawal by subject | 52 | 60 |
| Withdrew: Noncompliance with study drug | 0 | 5 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Ineligibility | 3 | 4 |
| Withdrew: Visit schedule issues | 1 | 2 |
| Withdrew: Patient moved | 2 | 2 |
Number of days from baseline (day 1 of core phase) to relapse as evaluated according the Csernansky criteria. A patient was considered to have relapsed if they met one or more of the following criteria: (1) psychiatric hospitalization; (2) an increase in the level of psychiatric care and an increase of 25 percent (%) from baseline in the Positive And Negative Syndrome Score (PANSS) total score (or an increase of 10 points if the baseline score was 40 or less); (3) deliberate self-injury; (4) suicidal or homicidal ideation that was clinically significant in the investigator's judgment; (5) violent behavior resulting in clinically significant injury to another person or property damage; (6) substantial clinical deterioration, defined as a change score of 6 ("much worse") or 7 ("very much worse") on the Clinical Global Impressions Scale (CGI-C); and/or (7) the required dose of the antipsychotic exceeds the maximum approved dose.
| days | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Time to First Relapse Event | 616 ± 10.9 | 603 ± 13.1 |
The proportion of patients achieving a treatment response, defined as a ≥30% decrease (i.e., improvement) in Positive and Negative Syndrome Scale (PANSS) total score from baseline to endpoint. The PANSS is a 30-item scale (Range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate increased severity of schizophrenia symptoms.
| percentage of participants | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Percentage of Treatment Responders | 75.6 (70.8 to 79.8) | 69.4 (64.5 to 73.9) |
Change from baseline in the PANSS: The PANSS is a 30-item scale (Range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.
| units on a scale | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Baseline score | 82.5 ± 12.03 | 81.5 ± 11.70 |
| change from baseline at Day 8 | -4.8 ± 5.93 | -3.7 ± 7.04 |
| change from baseline at Month 1 | -9.4 ± 10.91 | -8.8 ± 10.15 |
| change from baseline at Month 2 | -12.2 ± 12.19 | -12.3 ± 11.34 |
| change from baseline at Month 3 | -14.5 ± 11.72 | -15.0 ± 11.15 |
| change from baseline at Month 4 | -16.2 ± 13.03 | -16.8 ± 12.34 |
| change from baseline at Month 6 | -18.5 ± 13.67 | -18.6 ± 13.09 |
| change from baseline at Month 9 | -19.5 ± 14.72 | -20.1 ± 14.35 |
| change from baseline at Month 12 | -21.8 ± 13.32 | -21.2 ± 14.45 |
| change from baseline at Month 15 | -21.7 ± 14.56 | -21.9 ± 14.18 |
| change from baseline at Month 18 | -23.5 ± 13.56 | -22.8 ± 14.41 |
| change from baseline at Month 21 | -24.3 ± 13.60 | -23.7 ± 14.66 |
| change from baseline at Month 24 | -25.5 ± 14.42 | -24.6 ± 14.16 |
| change at Endpoint (LOCF) | -16.6 ± 21.42 | -14.1 ± 21.29 |
Change from baseline in positive symptom, negative symptom and general psychopathology subscales of the PANSS scale. The PANSS scale is designed to assess symptoms of schizophrenia by means of the 30-items. The PANSS scale provides subscores for 3 subscales, that is, the positive symptoms subscale (7 items, range 7-49), the negative symptoms subscale (7 items, range 7-49), and the general psychopathology subscale (16 items, range 16-112). Each item of the scale is to be scored on a scale of 1 (absent) to 7 (extreme). Higher scores indicate higher severity of schizophrenia symptoms.
| units on a scale | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Positive Subscale; Baseline score | 18.4 ± 3.97 | 18.3 ± 4.01 |
| Positive Subscale; change at Day 8 | -1.5 ± 2.11 | -1.3 ± 2.36 |
| Positive Subscale; change at Month 12 | -6.3 ± 4.10 | -6.2 ± 4.35 |
| Positive Subscale; change at Month 24 | -6.8 ± 4.39 | -6.7 ± 4.48 |
| Positive Subscale; change at Endpoint (LOCF) | -4.4 ± 6.61 | -3.8 ± 6.72 |
| Negative Subscale; Baseline score | 22.6 ± 4.55 | 22.3 ± 4.58 |
| Negative Subscale; change at Day 8 | -1.0 ± 1.90 | -0.8 ± 2.10 |
| Negative Subscale; change at Month 12 | -4.8 ± 4.69 | -4.7 ± 4.80 |
| Negative Subscale; change at Month 24 | -6.2 ± 5.19 | -5.9 ± 4.74 |
| Negative Subscale; change at Endpoint (LOCF) | -4.1 ± 6.13 | -3.7 ± 5.79 |
| General Psychopathology; Baseline score | 41.4 ± 6.73 | 40.8 ± 6.59 |
| General Psychopathology; change at Day 8 | -2.3 ± 3.58 | -1.6 ± 4.01 |
| General Psychopathology; change at Month 12 | -10.7 ± 7.19 | -10.3 ± 7.64 |
| General Psychopathology; change at Month 24 | -12.5 ± 7.63 | -12.0 ± 7.82 |
| General Psychopathology; change at Endpoint (LOCF) | -8.1 ± 10.96 | -6.7 ± 11.12 |
Change from baseline in schizophrenia symptoms were assessed through the following PANSS factor scores as described by Marder: (1) positive symptoms (range 8-56): sum of delusions, hallucinatory behavior, grandiosity, suspiciousness, stereotyped thinking, somatic concern, unusual thought content, lack of judgment and insight; (2) negative symptoms (range 7-49): sum of blunted affect, emotional withdrawal, poor rapport, passive social withdrawal, lack of spontaneity, motor retardation, and active social avoidance; (3) disorganized thoughts (range 7-49): sum of conceptual disorganization, difficulty in abstract thinking, mannerisms and posturing, disorientation, poor attention, disturbance of volition, and preoccupation; (4) uncontrolled hostility/excitement (range 4-28): sum of excitement, hostility, uncooperativeness and poor impulse control; (5) anxiety/depression (range 4-28): sum of anxiety, guilt feelings, tension, and depression. Higher scores indicate higher severity of symptoms
| units on a scale | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Positive Symptoms Factor Score; Baseline score | 22.9 ± 4.26 | 22.5 ± 4.39 |
| Positive Symptoms Factor Score; change at Day 8 | -1.5 ± 2.22 | -1.3 ± 2.50 |
| Positive Symptoms Factor Score; change at Month 12 | -6.9 ± 4.31 | -6.9 ± 4.76 |
| Positive Symptoms Factor Score; change at Month 24 | -7.6 ± 4.48 | -7.8 ± 4.95 |
| Positive Symptoms Factor Score; change at Endpoint | -5.0 ± 6.73 | -4.7 ± 6.80 |
| Negative Symptoms Factor Score; Baseline score | 22.0 ± 4.65 | 21.5 ± 4.95 |
| Negative Symptoms Factor Score; change at Day 8 | -1.0 ± 1.93 | -0.8 ± 2.25 |
| Negative Symptoms Factor Score; change at Month 12 | -5.1 ± 4.73 | -4.9 ± 4.88 |
| Negative Symptoms Factor Score; change at Month 24 | -6.5 ± 5.16 | -6.1 ± 5.05 |
| Negative Symptoms Factor Score; change at Endpoint | -4.3 ± 6.26 | -3.8 ± 6.08 |
| Disorganized Thoughts Factor; Baseline score | 19.5 ± 3.54 | 19.4 ± 3.41 |
| Disorganized Thoughts Factor; change at Day 8 | -1.0 ± 1.61 | -0.6 ± 2.06 |
| Disorganized Thoughts Factor; change at Month 12 | -4.6 ± 3.42 | -4.6 ± 3.78 |
| Disorganized Thoughts Factor; change at Month 24 | -5.4 ± 3.90 | -5.4 ± 3.82 |
| Disorganized Thoughts Factor; change at Endpoint | -3.7 ± 5.03 | -3.2 ± 5.16 |
| Uncontrolled Hostility/Excitement; Baseline score | 8.4 ± 2.71 | 8.3 ± 2.64 |
| Uncontrolled Hostility/Excitement; change at Day 8 | -0.7 ± 1.60 | -0.4 ± 1.47 |
| Uncontrolled Hostility/Excitement; change Month 12 | -2.3 ± 2.57 | -2.1 ± 2.62 |
| Uncontrolled Hostility/Excitement; change Month 24 | -2.7 ± 2.77 | -2.3 ± 2.73 |
| Uncontrolled Hostility/Excitement; change Endpoint | -1.5 ± 3.82 | -0.8 ± 3.87 |
| Anxiety/Depression Factor; Baseline score | 9.7 ± 2.74 | 9.8 ± 2.85 |
| Anxiety/Depression Factor; change at Day 8 | -0.8 ± 1.57 | -0.6 ± 1.72 |
| Anxiety/Depression Factor; change at Month 12 | -2.8 ± 2.67 | -2.7 ± 2.56 |
| Anxiety/Depression Factor; change at Month 24 | -3.3 ± 2.90 | -3.0 ± 2.78 |
| Anxiety/Depression Factor; change at Endpoint | -2.1 ± 3.51 | -1.8 ± 3.47 |
The Clinical Global Impression Severity (CGI-S) rating scale is a 7 point global clinical assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate higher impression of illness severity.
| units on a scale | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Baseline score | 3.9 ± 0.37 | 3.8 ± 0.40 |
| change from baseline at Day 8 | -0.1 ± 0.38 | -0.1 ± 0.43 |
| change from baseline at Month 1 | -0.3 ± 0.61 | -0.3 ± 0.61 |
| change from baseline at Month 2 | -0.4 ± 0.70 | -0.5 ± 0.71 |
| change from baseline at Month 3 | -0.6 ± 0.69 | -0.6 ± 0.69 |
| change from baseline at Month 4 | -0.7 ± 0.75 | -0.8 ± 0.71 |
| change from baseline at Month 6 | -0.8 ± 0.78 | -0.8 ± 0.73 |
| change from baseline at Month 9 | -0.9 ± 0.80 | -0.9 ± 0.78 |
| change from baseline at Month 12 | -1.0 ± 0.78 | -1.0 ± 0.80 |
| change from baseline at Month 15 | -0.9 ± 0.82 | -1.0 ± 0.80 |
| change from baseline at Month 18 | -1.0 ± 0.80 | -1.0 ± 0.78 |
| change from baseline at Month 21 | -1.0 ± 0.78 | -1.1 ± 0.82 |
| change from baseline at Month 24 | -1.1 ± 0.79 | -1.1 ± 0.80 |
| change from baseline at Endpoint (LOCF) | -0.7 ± 1.14 | -0.6 ± 1.12 |
The Clinical Global Impression-Change (CGI-C) rating scale is used to rate the change in severity of the patient's illness compared to baseline (day 1 of core phase) on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
| percentage of participants | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Month 24; Very Much Improved | 22.9 ± 22.9 | 21.7 ± 21.7 |
| Month 24; Much Improved | 52.9 ± 52.9 | 47.8 ± 47.8 |
| Month 24; Minimally Improved | 17.0 ± 17.0 | 20.8 ± 20.8 |
| Month 24; No change | 6.7 ± 6.7 | 7.7 ± 7.7 |
| Month 24; Minimally Worse | 0.0 ± 0.0 | 1.0 ± 1.0 |
| Month 24; Much Worse | 0.4 ± 0.4 | 1.0 ± 1.0 |
| Month 24; Very Much Worse | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Endpoint; Very Much Improved | 17.1 ± 17.1 | 14.2 ± 14.2 |
| Endpoint; Much Improved | 40.6 ± 40.6 | 35.8 ± 35.8 |
| Endpoint; Minimally Improved | 17.4 ± 17.4 | 21.9 ± 21.9 |
| Endpoint; No change | 10.6 ± 10.6 | 10.8 ± 10.8 |
| Endpoint; Minimally Worse | 5.1 ± 5.1 | 6.1 ± 6.1 |
| Endpoint; Much Worse | 9.1 ± 9.1 | 10.6 ± 10.6 |
| Endpoint; Very Much Worse | 0.0 ± 0.0 | 0.6 ± 0.6 |
The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100, divided into 10 equal intervals to rate degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on 4 domains there will be 1 total score. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.
| units on a scale | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Baseline score | 55.3 ± 11.31 | 55.3 ± 11.07 |
| change from baseline at Month 1 | 4.9 ± 7.78 | 4.3 ± 7.65 |
| change from baseline at Month 3 | 7.6 ± 8.91 | 7.7 ± 9.02 |
| change from baseline at Month 6 | 9.9 ± 10.08 | 10.8 ± 10.32 |
| change from baseline at Month 9 | 11.4 ± 11.28 | 11.9 ± 11.03 |
| change from baseline at Month 12 | 12.7 ± 10.78 | 12.3 ± 11.27 |
| change from baseline at Month 15 | 12.9 ± 11.05 | 12.9 ± 10.82 |
| change from baseline at Month 18 | 14.0 ± 11.44 | 13.3 ± 11.44 |
| change from baseline at Month 21 | 14.7 ± 12.3 | 14.0 ± 11.69 |
| change from baseline at Month 24 | 15.2 ± 12.72 | 14.6 ± 11.72 |
| change from baseline at Endpoint (LOCF) | 9.8 ± 15.41 | 8.7 ± 14.89 |
The Short Form-36 Health Survey (SF-36) is a measure of Participant-reported health status. It is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Two summary scale scores are computed based on weighted combinations of the 8 subscale scores: the Physical Component Summary and the Mental Component Summary. Each summary scale score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status.
| units on a scale | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Physical Component, Baseline score | 50.3 ± 8.04 | 50.6 ± 7.83 |
| Physical Component, change at Month 6 | 1.2 ± 6.92 | 1.3 ± 6.52 |
| Physical Component, change at Month 12 | 1.6 ± 7.62 | 1.2 ± 7.08 |
| Physical Component, change at Month 24 | 2.2 ± 8.40 | 2.1 ± 6.74 |
| Physical Component, change at Endpoint (LOCF) | 1.7 ± 8.52 | 1.4 ± 7.40 |
| Mental Component, Baseline score | 32.1 ± 12.62 | 31.4 ± 12.92 |
| Mental Component, change at Month 6 | 8.2 ± 11.58 | 9.1 ± 12.43 |
| Mental Component, change at Month 12 | 10.5 ± 11.75 | 11.6 ± 12.77 |
| Mental Component, change at Month 24 | 12.0 ± 13.34 | 12.3 ± 12.83 |
| Mental Component, change at Endpoint (LOCF) | 9.0 ± 14.99 | 8.7 ± 14.37 |
The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analog scale, with 0 representing the worst imaginable health state and 100 representing the best imaginable health state. The EQ VAS is used as a quantitative measure of health outcome as judged by the individual respondent.
| units on a scale | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Baseline score | 57.5 ± 20.94 | 57.6 ± 20.41 |
| change from baseline at Month 6 | 10.6 ± 17.31 | 11.9 ± 17.00 |
| change from baseline at Month 12 | 15.0 ± 17.38 | 15.6 ± 18.32 |
| change from baseline at Month 24 | 17.9 ± 19.48 | 18.6 ± 17.36 |
| change from baseline at Endpoint (LOCF) | 13.0 ± 22.87 | 11.9 ± 21.54 |
The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "full health" and 0 representing dead. A higher score indicates an improvement in health in the Health Status Index.
| units on a scale | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Baseline score | 0.80 ± 0.173 | 0.78 ± 0.181 |
| change from baseline at Month 6 | 0.06 ± 0.181 | 0.09 ± 0.157 |
| change from baseline at Month 12 | 0.08 ± 0.185 | 0.11 ± 0.179 |
| change from baseline at Month 24 | 0.10 ± 0.201 | 0.12 ± 0.161 |
| change from baseline at Endpoint (LOCF) | 0.06 ± 0.224 | 0.08 ± 0.192 |
The SWN-S is a patient self-rated scale developed to measure the subjective well-being for the previous 7 days of a patient under neuroleptic treatment. The SWN-S consists of 20 items (each item is rated from 1=not at all to 6=very much). The total score ranges from 20 to 120 with higher score indicating greater subjective well-being.
| units on a scale | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Baseline score | 76.5 ± 17.02 | 76.7 ± 17.07 |
| change from baseline at Month 6 | 8.4 ± 14.06 | 9.1 ± 14.40 |
| change from baseline at Month 12 | 11.4 ± 15.81 | 11.1 ± 17.02 |
| change from baseline at Month 24 | 13.4 ± 18.14 | 13.1 ± 15.76 |
| change from baseline at Endpoint (LOCF) | 9.7 ± 19.17 | 8.3 ± 17.58 |
Patient's satisfaction with medication was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM is divided into 4 subscales (effectiveness, side effects, convenience, and global satisfaction), with the value of each subscale ranging from 0 to 100. Higher scores indicate greater treatment satisfaction.
| units on a scale | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Effectiveness; Baseline score | 61.9 ± 16.97 | 59.5 ± 16.82 |
| Effectiveness; change at Month 12 | 6.7 ± 22.72 | 6.6 ± 21.99 |
| Effectiveness; change at Month 24 | 8.5 ± 21.75 | 12.4 ± 20.69 |
| Effectiveness; change at Endpoint (LOCF) | 3.8 ± 23.47 | 4.5 ± 25.31 |
| Side-effects; Baseline score | 91.3 ± 19.74 | 87.3 ± 23.41 |
| Side-effects; change at Month 12 | 2.1 ± 22.71 | 2.5 ± 25.66 |
| Side-effects; change at Month 24 | 2.8 ± 20.93 | 3.5 ± 23.96 |
| Side-effects; change at Endpoint (LOCF) | -1.4 ± 25.59 | 0.7 ± 28.24 |
| Convenience; Baseline score | 67.1 ± 16.66 | 68.4 ± 16.45 |
| Convenience; change at Month 12 | 8.4 ± 19.10 | 1.0 ± 17.79 |
| Convenience; change at Month 24 | 10.4 ± 20.49 | 4.7 ± 17.69 |
| Convenience; change at Endpoint (LOCF) | 7.4 ± 21.24 | 0.3 ± 21.68 |
| Global Satisfaction; Baseline score | 64.0 ± 18.13 | 62.8 ± 18.31 |
| Global Satisfaction; change at Month 12 | 8.2 ± 18.89 | 7.0 ± 21.18 |
| Global Satisfaction; change at Month 24 | 8.6 ± 21.06 | 9.2 ± 20.39 |
| Global Satisfaction; change at Endpoint (LOCF) | 3.0 ± 25.01 | 1.0 ± 26.76 |
Physician's treatment satisfaction was assessed using the physician's treatment satisfaction scale which is designed to rate 4 aspects of treatment (efficacy, safety, mode of administration, and overall satisfaction), each on a scale ranging from 1 (extremely satisfied) to 7 (extremely dissatisfied).
| units on a scale | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Efficacy; Baseline score | 2.7 ± 0.79 | 2.8 ± 0.79 |
| Efficacy; change at Month 12 | -0.5 ± 1.03 | -0.4 ± 0.92 |
| Efficacy; change at Month 24 | -0.6 ± 1.10 | -0.6 ± 0.98 |
| Efficacy; change at Endpoint (LOCF) | -0.2 ± 1.46 | 0.0 ± 1.43 |
| Safety; Baseline score | 2.4 ± 0.80 | 2.6 ± 0.77 |
| Safety; change at Month 12 | -0.4 ± 0.97 | -0.2 ± 0.90 |
| Safety; change at Month 24 | -0.4 ± 0.97 | -0.3 ± 1.04 |
| Safety; change at Endpoint (LOCF) | -0.2 ± 1.19 | -0.0 ± 1.18 |
| Mode of Administration: Baseline score | 2.6 ± 0.86 | 2.6 ± 0.83 |
| Mode of Administration: change at Month 12 | -0.7 ± 1.02 | -0.0 ± 0.92 |
| Mode of Administration: change at Month 24 | -0.7 ± 1.09 | -0.1 ± 0.92 |
| Mode of Administration: change at Endpoint (LOCF) | -0.5 ± 1.16 | 0.0 ± 1.04 |
| Overall Satisfaction; Baseline score | 2.6 ± 0.78 | 2.7 ± 0.74 |
| Overall Satisfaction; change at Month 12 | -0.5 ± 0.95 | -0.3 ± 0.84 |
| Overall Satisfaction; change at Month 24 | -0.6 ± 1.00 | -0.3 ± 0.86 |
| Overall Satisfaction; change at Endpoint (LOCF) | -0.2 ± 1.25 | 0.1 ± 1.16 |
Number of participants with a relapse event with relapses evaluated according the Csernansky criteria. A patient was considered to have relapsed if they met one or more of the following criteria: (1) psychiatric hospitalization; (2) an increase in the level of psychiatric care and an increase of 25% from baseline in the PANSS total score (or an increase of 10 points if the baseline score was 40 or less); (3) deliberate self-injury; (4) suicidal or homicidal ideation that was clinically significant in the investigator's judgment; (5) violent behavior resulting in clinically significant injury to another person or property damage; (6) substantial clinical deterioration, defined as a change score of 6 ("much worse") or 7 ("very much worse") on the Clinical Global Impressions Scale (CGI-C); and/or (7) the required dose of the antipsychotic exceeds the maximum approved dose.
| number of participants | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| No | 300 | 287 |
| Yes | 52 | 76 |
Collected over from randomization until maximally month 24. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paliperidone Palmitate | — | 42/376 (11.2%) | 208/376 (55.3%) |
| Oral Antipsychotics | — | 48/388 (12.4%) | 208/388 (53.6%) |
| Event | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| SchizophreniaPsychiatric disorders | 21/376 | 22/388 |
| Psychotic disorderPsychiatric disorders | 7/376 | 8/388 |
| Schizophrenia, paranoid typePsychiatric disorders | 3/376 | 4/388 |
| AnxietyPsychiatric disorders | 2/376 | 0/388 |
| AgitationPsychiatric disorders | 1/376 | 2/388 |
| Alcohol abusePsychiatric disorders | 0/376 | 2/388 |
| Suicide attemptPsychiatric disorders | 0/376 | 2/388 |
| Cardiac arrestCardiac disorders | 1/376 | 0/388 |
| Abdominal painGastrointestinal disorders | 1/376 | 0/388 |
| Cholecystitis chronicHepatobiliary disorders | 1/376 | 0/388 |
| Event | Paliperidone Palmitate | Oral Antipsychotics |
|---|---|---|
| Weight increasedInvestigations | 58/376 | 65/388 |
| InsomniaPsychiatric disorders | 42/376 | 39/388 |
| HeadacheNervous system disorders | 40/376 | 34/388 |
| NasopharyngitisInfections and infestations | 25/376 | 20/388 |
| Injection site painGeneral disorders | 24/376 | 0/388 |
| AnxietyPsychiatric disorders | 22/376 | 23/388 |
| Suicidal ideationPsychiatric disorders | 20/376 | 23/388 |
| TremorNervous system disorders | 22/376 | 17/388 |
| AkathisiaNervous system disorders | 21/376 | 22/388 |
| SomnolenceNervous system disorders | 13/376 | 22/388 |
Whole Intent-to-Treat population: All randomized patients who received at least 1 dose of study medication during the screening or treatment phase
| Age, Continuous(years) | Paliperidone Palmitate | Oral Antipsychotics | Total |
|---|---|---|---|
| Mean | 32.5 ± 10.73 | 32.4 ± 10 | 32.5 ± 10.36 |
| Sex: Female, Male(Participants) | Paliperidone Palmitate | Oral Antipsychotics | Total |
|---|---|---|---|
| Female | 147 | 171 | 318 |
| Male | 229 | 217 | 446 |
| Region of Enrollment(participants) | Paliperidone Palmitate | Oral Antipsychotics | Total |
|---|---|---|---|
| AUSTRIA | 0 | 1 | 1 |
| BELGIUM | 7 | 5 | 12 |
| BULGARIA | 15 | 15 | 30 |
| CROATIA | 12 | 12 | 24 |
| CZECH REPUBLIC | 14 | 21 | 35 |
| EGYPT | 16 | 14 | 30 |
| ESTONIA | 2 | 3 | 5 |
| FRANCE | 4 | 4 | 8 |
| GERMANY | 3 | 2 | 5 |
| HUNGARY | 15 | 16 | 31 |
| ISRAEL | 6 | 5 | 11 |
| ITALY | 10 | 11 | 21 |
| JORDAN | 15 | 11 | 26 |
| KOREA, REPUBLIC OF KOREA | 2 | 4 | 6 |
| LITHUANIA | 13 | 14 | 27 |
| POLAND | 11 | 11 | 22 |
| ROMANIA | 13 | 14 | 27 |
| RUSSIAN FEDERATION | 90 | 90 | 180 |
| SLOVAKIA | 13 | 14 | 27 |
| SOUTH AFRICA | 26 | 24 | 50 |
| SPAIN | 3 | 4 | 7 |
| TAIWAN, PROVINCE OF CHINA | 4 | 5 | 9 |
| TURKEY | 11 | 9 | 20 |
| UKRAINE | 71 | 79 | 150 |
The record gives a start of Feb 2010, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone
Janssen-Cilag International NV →